Quantcast
Last updated on April 19, 2014 at 8:45 EDT

Latest ACE inhibitors Stories

2010-09-28 07:00:00

BURLINGTON, Mass., Sept. 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, owing to increasing generic availability of antihypertensive agents, the hypertension drug market will decline from $26 billion in 2009 to $23 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The Pharmacor 2010 findings from the topic entitled Hypertension reveal that the...

2010-08-20 13:50:34

Expensive brand-name medications to lower blood pressure are no better at preventing cardiovascular disease than older, generic diuretics, according to new long-term data. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), led by Paul Whelton, MB, MD, MSc, president and CEO of Loyola University Health System, examined the comparative value of different blood pressure-lowering medications. More than 33,000 patients with high blood pressure were randomly...

24b28e948cab6cdeed405b8bb1e0ba851
2010-08-13 08:52:20

New long-term data from landmark ALLHAT study Expensive brand-name medications to lower blood pressure are no better at preventing cardiovascular disease than older, generic diuretics, according to new long-term data from a landmark study. Paul Whelton, MB, MD, MSc, reported the results on Aug. 13 at the plenary session of the China Heart Congress and International Heart Forum in Beijing. Whelton is president and CEO of Loyola University Health System and chairman of the Antihypertensive and...

2010-06-13 14:59:00

RIDGEFIELD, Conn., June 13 /PRNewswire/ -- Telmisartan, an angiotensin receptor blocker, is one of the best researched drugs worldwide. It has been studied in clinical trials in more than 50,000 patients. Its positive safety profile has been confirmed also in a market exposure of 34.5 million patient years. Convincing safety data for patients with a high cardiovascular risk were collected in the three long-term outcome trials ONTARGET, PRoFESS and TRANSCEND which followed some of the...

2010-03-26 07:23:35

Millions of patients with high blood pressure and heart failure take a class of drugs known as ACE (angiotensin-converting enzyme) inhibitors. These drugs prevent the body from processing angiotensin II, a hormone that constricts blood vessels. Scientists at Emory University, University of Alabama, Birmingham, and Fukuoka University in Japan have shown that another enzyme present in the heart called chymase is also capable of processing angiotensin II. Adding drugs that interfere with chymase...

2010-03-02 23:01:00

HOBOKEN, N.J., March 3 /PRNewswire/ -- An estimated one in ten adults suffers from kidney disease, according to the National Institute of Diabetes and Digestive and Kidney Diseases. A leading cause of kidney disease is hypertension, which effects one out of every four U.S. adults. Chronically high blood pressure damages capillaries of the kidneys which in turn affects the organ's ability to filter waste and remove excess fluids from the body. A study published in the March 2010 issue of...

2010-02-08 12:48:00

BALTIMORE, Feb. 8 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (U.S. FDA) has granted final approval for its Amlodipine/Benazepril 2.5mg/10mg, 5mg/10mg, 5mg/20mg and 10mg/20mg capsules. Commercial shipments of the product have already commenced. Lupin's Amlodipine/Benazepril capsules are the AB-rated generic equivalent of Novartis' Lotrel® capsules indicated for the treatment of hypertension. Amlodipine/Benazepril...

2010-01-25 07:30:00

NANTONG, China, Jan. 25 /PRNewswire-Asia-FirstCall/ -- Sinobiopharma, Inc. ("Sinobiopharma" or, the "Company") (OTC Bulletin Board: SNBP) is pleased to announce that its production facility for solid dosage Perindopril has passed the required Chinese State Food and Drug Administration (SFDA) inspection and is now approved for production and marketing. Sinobiopharma had received SFDA approval for its formulation of Perindopril, the first version of the drug to be developed in China, in...

2009-10-19 07:30:00

RIDGEFIELD, Conn., Oct. 19 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular...

2009-09-24 09:05:53

Scientists at Queen Mary, University of London have made an important discovery in understanding what causes arteries to clog up. They have discovered that an enzyme called matrix metalloproteinase-8 plays a crucial role in raising blood pressure and causing abnormal build-up of cells in the arteries "“ both of which increase the risk of heart disease. Heart disease is the number one cause of death in the UK. The scientists say that their research could lead to new drugs for treating...